Danaher Beats Out Cytyc, Ventana In Battle For Vision Systems
This article was originally published in The Gray Sheet
Executive Summary
Cytyc and Ventana are bowing out of a bidding war for cancer and infectious disease detection equipment maker Vision Systems, which says it prefers a richer offer valued at $520 mil. from diversified industrial firm Danaher
You may also be interested in...
Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.
Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says